Bladder cancer is a major public health problem worldwide, with relatively high morbidity. However, there are few studies on drug development for bladder cancer. Troglitazone (TZ) is a synthetic ligand of peroxisome proliferator-activated receptor-g, and it can induce apoptosis and autophagy in a variety of cancer cells. Several studies have indicated that TZ affects both cell growth and differentiation progress and has an inhibitory effect on urinary cancer cells. However, this drug's effect on bladder cancer cells remains largely unknown. Here, we report that TZ induced autophagy and enhanced apoptosis in T24 cells. Autophagic blockage resulted in the attenuation of TZ-dependent apoptosis. Necrostatin-1, an inhibitor of necroptosis, was found to reduce light chain 3 (LC3)-II accumulation and partially rescue the loss of cell viability induced by TZ. It was demonstrated that TZ activated autophagy concurrent with the activation of the adenosine monophosphate-dependent protein kinase (AMPK) signaling pathway. AMPK inhibition led to a reduction in LC3-II levels, which were responsive to TZ treatment. Overall, TZ induced multiple types of programmed cell death in bladder cancer cells, and while the autophagy induced by the agonist contributed to the apoptotic process, crosstalk or switching between the different types of cell death likely occurred.
INTRODUCTION
Bladder cancer is one of the highest-morbidity tumors in the urinary system. In China, the incidence rate of bladder cancer is the highest among those of all urological tumors. 1, 2 In total, 15-30% of patients progress to muscle-invasive bladder cancer in 5 years. 3 Muscleinvasive bladder cancer is a fatal disease, with a poor 5-year survival rate. 4, 5 Drug resistance is always an intractable problem in cancer therapy, and autophagy may have an important role in this problem. Accumulating evidence indicates that autophagy may be a protective mechanism. 6, 7 Autophagy is a highly conserved process that includes macroautophagy, microautophagy and chaperone-mediated autophagy. Macroautophagy (hereafter referred to as autophagy) is considered to be an important way to degrade long-lived proteins and organelles. 8 In cancer occurrence and development, autophagy most likely has a dual role. 9 In recent years, knowledge of cell death has greatly increased, and a new programmed cell death (PCD) pathway, necroptosis, has been identified. 10 Autophagy and other types of cell death have complicated interactions that need to be further studied.
Troglitazone (TZ) is a synthetic agent that belongs to the thiazolidinedione class of antidiabetic drugs, which target peroxisome proliferator-activated receptor-g (PPARg), a transcription factor in the nuclear receptor family. 11, 12 Over the past several years of extensive studies, these drugs have been shown to be surprisingly effective in regulating cell growth, differentiation and apoptosis. Moreover, several studies have indicated that certain thiazolidinediones, including ciglitazone, pioglitazone and TZ, present an inhibitory effect on or induce apoptosis in urinary cancer cells. [13] [14] [15] The inhibition of the mammalian target of rapamycin (mTOR) activates the unc-51-like kinase (the mammalian functional homolog of ATG1) through the energy sensor adenosine monophosphate-dependent protein kinase (AMPK) and initiates autophagy upon nutrient deprivation. 16 In muscle cells, studies have revealed that TZ can rapidly induce the phosphorylation/ activation of AMPK, a fuel-sensing enzyme that turns on catabolic pathways to produce ATP when activated. 17 Nevertheless, whether TZ can induce autophagy in bladder cancer cells has not been investigated.
In the present study, we found TZ-induced autophagy, apoptosis and necroptosis in bladder cancer cells. The deployment of either necroptosis or an AMPK inhibitor attenuated the TZdependent autophagy. Interestingly, autophagic inhibition led to a reduction in the caspase-dependent apoptosis induced by TZ.
MATERIALS AND METHODS

Chemicals and antibodies
In this study, 3-methyladenine (M9281), protease cocktail inhibitor (P8340, AEBSF, aprotinin, bestatin, E-64, leupeptin and pepstatin A), necrostatin-1 (Nec-1; N9037), GW9662 (M6191), TZ (T2573) and a polyclonal antibody against light chain 3 (LC3) (L7543) were purchased from Sigma-Aldrich (St Louis, MO, USA). Z-VAD-FMK (Z-V-FMK; FMK001) was purchased from R&D Systems (Minneapolis, MN, USA). Antibodies against poly (ADP-ribose) polymerase (PARP; 9542), phosphor-AMPKa (Thr172; 2535) and total-AMPK (2532), phospho (Thr389; 9209)-P70S6K (S6K1; 2708) and phospho-(Ser2448; 5336) and total mTOR (2983) were purchased from Cell Signaling Technology (Beverley, MA, USA). Antibodies against actin (sc-1616-R) and p62 (sc-28359) were from Santa Cruz Biotechnology (Dallas, TX, USA). 1 Cell culture and plasmid
The human bladder cancer cells T24 and EJ were maintained in McCoy's 5A (KeyGEN, KGM5ASY) supplemented with 10% fetal bovine serum (GIBCO, 16000) and antibiotics. The cells were split overnight and grown to 50% confluence before treatment.
The green fluorescence protein (GFP) and microtubule-associated protein 1 LC3 fusion protein (GFP-LC3) expression plasmid were kind gifts of Dr Tamotsu Yoshimori (Osaka University, Japan). Cells at B60% confluence were transfected with GFP-LC3 using Lipofectamine 2000 reagent (Invitrogen, Grand Island, NY, USA). After transfection for 24 h, the cells were split, subjected to various treatments and then fixed with 4% paraformaldehyde for 5 min. The results were then analyzed using a scanning confocal microscope (Olympus, Osaka, Japan).
Western blotting
Whole-cell lysates were prepared in lysis buffer consisting of Triton X-100/ glycerol, which contained 50 mM Tris-HCl (pH 7.4), 4 mM EDTA, 2 mM EGTA and 1 mM dithiothreitol supplemented with 1% Triton X-100 and protease inhibitors (an inhibitor cocktail from Sigma-Aldrich and PMSF). The lysates were then separated on SDS-PAGE gel (15, 10 or 8%, according to the molecular weights of the proteins of interest) and transferred to a polyvinylidene fluoride membrane. Western blotting was performed using the appropriate primary antibodies and suitable horseradish peroxidaseconjugated secondary antibodies, followed by detection by enhanced chemiluminescence (Pierce Chemical, 34080, Rockford, IL, USA).
RNA interference
Cells at B30% confluence were transfected with siRNA using DharmaFECT (Dharmacon, T2001, Denver, CO, USA) following the manufacturer's instructions. After transfection for 48 h, the cells were split and used for experiments.
Cell proliferation assay
Cells were plated in 96-well plates (10 000 cells per well) in 100 ml complete culture medium 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS). After overnight culture, the medium was replaced with complete medium that was either drug free or contained TZ or other chemicals. The cells were cultured for various periods, and cellular viability was determined using a CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay (Promega, G1111, Madison, WI, USA).
Electron microscopy T24 cell samples were washed three times with phosphate-buffered saline (PBS), trypsinized and collected by centrifugation. The cell pellets were fixed with 4% paraformaldehyde overnight at 4 1C, fixed with 1% OsO4 in cacodylate buffer at room temperature for 1 h and dehydrated stepwise with ethanol. The dehydrated pellets were rinsed with propylene oxide for 30 min and then embedded in Spurr resin for sectioning. Images of thin sections were observed under a transmission electron microscope (JEM1230, Japan Electronics, Tokyo, Japan).
Confocal microscopy T24 cells were transfected with the GFP-LC3 expression plasmid, and after 24 h the cells were treated with TZ. The GFP-LC3 fluorescence was imaged via confocal microscopy (TCS SP5, Leica, Oskar, Germany).
Immunofluorescence staining T24 cells were grown on glass coverslips. The cells were treated with TZ (25 mM) for 1 h, washed with Ca 2 þ -and Mg 2 þ -free PBS (CMF-PBS), fixed with freshly prepared 3% paraformaldehyde for 30 min at 4 1C and permeabilized via a 3-min incubation in CMF-PBS containing 0.1% Triton X-100 and 0.5% BSA at room temperature. The cells were then washed three times with CMF-PBS, blocked in CMF-PBS containing 3% BSA for 30 min and incubated with anti-LC3 antibody in the presence of 0.1% Triton X-100 and 0.5% BSA. Incubation with the secondary antibody (donkey anti-rabbit IgG labeled with Cy3) was conducted in the same solution. Both the primary and the secondary antibody solutions were precleared by centrifugation at 13 000 g for 15 min. Images were acquired via fluorescence microscopy, and the final arrangement of all images was performed using Adobe Photoshop.
Statistical analysis
Normally distributed data are shown as the mean±s.d. These data were analyzed using one-way analysis of variance and the Student-NewmanKeuls post hoc test.
RESULTS
TZ induces the formation of autophagosomes and autophagic flux
Under an electron microscope, the increased formation of autophagosomes was observed in TZ-treated T24 cells compared with the control cells (Figure 1a) . To further monitor autophagosome formation in the TZ-treated cells, T24 cells were transfected with a GFP-LC3 fusion protein (serving as a specific marker of autophagosomes). When autophagy is induced and autophagosomes form, GFP-LC3 should gather to form punctate areas, which can be detected by confocal microscopy. The results showed that the TZ-treated cells had more punctate staining with GFP-LC3, whereas the GFP-LC3 staining remained diffuse in the control cells (Figure 1b) . To confirm the aforementioned results, we performed immunofluorescence staining following the treatment of T24 cells with TZ. Compared with staining in a dimethylsulfoxide control (Ctrl), TZ increased the punctate staining of LC3 (Figure 1c ). Together with observations by electron and confocal microscopy, the results indicate that TZ increased the formation of autophagosomes.
LC3, a homolog of Atg8 in mammalian cells, is initially synthesized in an unprocessed form. This protein, lacking certain amino acids in the C terminus, forms LC3-I and is ultimately modified into a phosphatidylethanolamine-conjugated form, LC3-II. LC3-II is the only protein that is associated with complete autophagosomes, so the ratio of LC3-II to actin is an accurate indicator of autophagy. 18 In the immunoblotting assay, we observed that TZ increased the ratio of LC3-II to actin relative to the ratio in the controls in a time-and concentration-dependent manner (Figure 2a) . Additionally, TZ treatment caused a decrease in the levels of p62/SQSTM1, an indicator of autophagic flux (Figure 2a) , 19, 20 confirming that TZ increases autophagic flux in T24 cells. Similar results were obtained in EJ cells, another bladder cancer cell line (Figure 2b) . mTOR inhibits autophagy, and its kinase activity can be detected by measuring the phosphorylation of its substrates, such as p70S6 kinase (S6K1). 21 As shown in Figure 2c , TZ was able to attenuate the phosphorylation of both mTOR and S6K1, suggesting that this agent induces autophagy by inhibiting the mTOR/S6K1 pathway. Because mounting evidence indicates that thiazolidinediones can exert metabolic effects independent of PPARg, 22, 23 we next examined the autophagic process in the presence of GW9662, an irreversible antagonist of PPARg. GW9662 failed to affect LC3-II accumulation (Figure 2d ), indicating that TZ-induced autophagy is independent of PPARg.
Autophagy induced by TZ precedes and contributes to apoptosis in T24 cells It has been reported that PPARg agonists (for example, TZ and 15d-PGJ2) induce apoptosis in bladder cancer cells. 13, 24 PARP, the substrate of caspase, is cleaved when DNA is damaged and cells are undergoing apoptosis. Therefore, the cleavage of PARP is often used as an apoptotic marker. 25 We found that TZ induced PARP cleavage in a time-and dose-dependent manner. In contrast to LC3-II accumulation, the cleavage of PARP occurred relatively later after TZ challenge (Figure 2a) , implying that the autophagy induced by TZ precedes apoptosis.
An inhibitor of PI3K, 3-methyladenine, is a widely used inhibitor of autophagy. 26 In the present study, we determined that the presence of 3-methyladenine was able to reduce TZ-dependent LC3-II accumulation (Figure 2e ). Interestingly, 3-methyladenine was demonstrated to decrease TZ-induced apoptosis, as measured based on the cleavage of PARP (Figure 2f) . Thus, the autophagy induced by TZ contributed to and enhanced the apoptotic process in T24 cells.
TZ causes multiple types of PCD, including necroptosis
To investigate the type of PCD induced in T24 cells, we detected cellular viability using the MTS assay. As shown in Figure 3 , cell viability decreased in a time-and concentration-dependent manner. Unexpectedly, the TZ-induced loss of cell viability was only partially rescued in the presence of Z-V-FMK, a pan-caspase inhibitor, 27 whereas Nec-1, an inhibitor of necroptosis, was able to recover cell viability. 28 Thus, TZ was able to induce both apoptosis and necroptosis in T24 cells.
Z-V-FMK and Nec-1 function differentially in TZ-induced autophagy To verify the relationship between TZ-induced cell death and autophagy, Z-V-FMK and Nec-1 were used as follows. Notably, whereas Z-V-FMK was revealed to enhance TZ-induced autophagy (Figure 4a ), Nec-1 was found to attenuate the TZ-induced LC3-II increase (Figure 4a and b) . Moreover, Z-V-FMK was able to completely block the cleavage of PARP, whereas Nec-1 demonstrated no obvious sign of affecting the apoptotic process induced by TZ (Figure 4c) . The results indicated that Z-V-FMK and Nec-1 function differentially in TZ-dependent autophagy. Moreover, it appeared that the cells might convert to another cell death pathway when one pathway was inhibited and the insult persisted. Taking these results together with the findings of the MTS assay, we speculated that crosstalk and interactions between different PCD pathways existed in the TZ-treated T24 cells ( Figures  3 and 4) . TZ induces autophagy through AMPK signaling AMP-activated protein kinase, the sensor of energy in the cell, phosphorylates unc-51-like kinase1 in response to nutrient deprivation to control unc-51-like kinase1 kinase function and the induction of autophagy. 29 Here, we found that TZ treatment increased the phosphorylation of AMPKa (Figure 5a ). Compound C, an inhibitor of AMPK, was found to attenuate TZ-induced autophagy in T24 cells (Figure 5b) . To confirm AMPK's function, a specific siRNA was used to knock down the expression of the AMPK protein. In agreement with the result in Compound C-treated cells, AMPK deprivation was shown to remarkably inhibit TZ-induced autophagy (Figure 5c ). Given that AMPK has an essential role in mediating autophagy, we assumed that TZ induces autophagic progress by activating the AMPK signaling pathway in T24 cells. Whereas necroptosis may contribute to autophagy, the inhibition of apoptosis is likely to attenuate autophagic strength (Figure 5d ).
DISCUSSION
One of the processes by which normal cells become cancerous involves the deregulation of PCD. Cancerous growth is one of the most difficult diseases to treat, given that there is no one apparent cause and that targeting only one pathway does not generally generate quantifiable improvement. To have a truly effective cancer therapy, multiple pathways must be targeted at the same time. In recent years, more and more people have realized that autophagy is important for cancer development and treatment. Initially, as a survival mechanism under stress conditions, autophagy can be a protective mechanism against cancer development. 6, 30, 31 Additionally, autophagy can suppress a tumor or even kill cancer cells. 32, 33 Although the role of autophagy in cancer treatment still needs to be further investigated, targeting autophagy in cancer will provide very promising opportunities for new drug development. Nevertheless, there are few studies on autophagy and fewer studies discussing autophagy and drug development in bladder cancer. In the present study, we observed that TZ induced mixed PCD, including autophagy, apoptosis and necroptosis, in bladder cancer cells.
Generally, three main types of cell death processes, with distinctive morphological features, have been described in the literature. Normally, all three forms of PCD must occur to maintain cell homeostasis. Concerning the relationship between autophagy and apoptosis, one study has suggested that autophagy has three types of relationships with apoptosis: partner, enabler and antagonist. 34 In the current study, we found that autophagy may be upstream of apoptosis. When apoptosis was interrupted, autophagy accumulated. In contrast, necroptosis may be an inducer of autophagy. When necroptosis is inhibited, apoptosis may be a substitute for cell death.
AMPK signaling is essential for autophagic regulation, 35 ,36 yet the inactivation of mTOR by AMPK has yielded controversial results regarding its effect on autophagy. Samari et al. 37 found that activation of AMPK in hepatocytes strongly suppresses autophagy. In contrast, Meley et al. 38 reported that AMPK is essential for autophagy. Here, we found that TZ stimulated autophagy in T24 cells, accompanied by an increase in AMPK phosphorylation. The inhibition of AMPK either chemically or genetically attenuated TZ-dependent autophagy. Thus, we assumed that AMPK most likely regulated autophagy in a cell type-and context-dependent manner. 39 In summary, we demonstrated TZ-induced autophagy in T24, a bladder cancer cell line. Most importantly, we showed that TZinduced autophagy contributed to apoptosis, which was accompanied by necroptosis. We demonstrated that TZ induced a mixture of types of PCD, among which there existed intricate crosstalk. The data presented here and future work in this direction will provide important clues regarding potential drug targets in bladder cancer. 
